<DOC>
	<DOC>NCT00843518</DOC>
	<brief_summary>The purpose of this study is to determine whether this drug can help symptoms of aggression and agitation in patients with Alzheimer's disease.</brief_summary>
	<brief_title>Treatment for Aggression and Agitation in Patients With Alzheimer's Disease</brief_title>
	<detailed_description>The primary purpose of this study is to help answer the following research questions: - Whether this drug can help symptoms of aggression and agitation in subjects with Alzheimer's Disease. - The safety of this drug and any side effects that might be associated with it. - How this drug compares to placebo. During the 12-week period of this study, the patient will have an equal chance of receiving 1 of the 2 treatment groups the active drug or the placebo.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<criteria>Communitydwelling patients with a diagnosis of probable Alzheimer's disease (AD), based on the disease diagnostic criteria, and with Mini Mental State Examination (MMSE) score from 6 to 26 inclusive, NPI10 total score greater than or equal to 10, and significant neuropsychiatric symptoms. Are men or women at least 60 years old. Weigh greater than or equal to 45 kg. Have clinically significant and persistent verbal or physical agitation and/or verbal or physical aggression behaviors that are disruptive to daily functioning or potentially harmful. Understand English. Have a reliable and actively involved caregiver who must be able to communicate in English and be willing to comply with protocol requirements. Have delirium. Meet criteria for vascular dementia. Have an MRI or CT scan on file since the onset of symptoms of AD and performed within the past 24 months that is inconsistent with a diagnosis of AD. Have a current, required use or expected use of psychoactive drugs or other medications not allowed in this trial. Have currently active significant medical problems that are not allowed in this trial or other brain disorders. Have received acetylcholinesterase inhibitor (AChEIs) or memantine for less than 4 months, or have less than 2 months of stable therapy on these treatments by Visit 2.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Agitation and Aggression</keyword>
</DOC>